^
Association details:
| Biomarker: | NTRK3 fusion |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Papillary Thyroid Cancer: Consider systemic therapy...Larotrectinib or entrectinib for patients with NTRK gene fusion-positive advanced solid tumors
Title:
New sarcoma drug approved for use in England
Excerpt:
We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
Source:
Title:
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Excerpt:
Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer….14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1...The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours.
DOI:
10.1016/S1470-2045(18)30119-0
Trial ID:
Source:
Title:
Larotrectinib reduced tumor size in TRK fusion‐positive pediatric PTC.
Published date:
09/20/2023
Excerpt:
We retrospectively studied patients with NTRK fusion‐positive pediatric PTC who received the selective TRK inhibitor larotrectinib and had ≥1 year of follow‐up after treatment cessation….Patient D had a partial response (‐35%) after 8 months of larotrectinib, and after 13 months, 123I scan showed no uptake. 131I was not given and, 13 months after stopping larotrectinib therapy, the disease was unchanged....Larotrectinib reduced tumor size in TRK fusion‐positive pediatric PTC.
